The FDA has been a little active recently and not only from changes but also from controversies. I think that some of the changes certainly could be seen as tailwinds but the increased variability of decisions and actions are perhaps more important. Even if announced changes are positive, when the industry has to make capital […]
February 11th Biotech Update
The still dominated by the metabolic franchise, with GLP-1s representing one of the largest value creation cycles in sector history. One has to think that the fate of this market plays a large part of generalist interest going forward. Shares of NOVO and LLY have been highly sensitive to competitive dynamics, supply constraints, and incremental […]
Strategic Analysis: LibertyStream Infrastructure (VLTLF) – The Modular Lithium Disruption
Chimera Research Group Critical Minerals Equity Note LibertyStream Infrastructure Partners Inc. (TSXV: LIB | OTCQB: VLTLF) Company Achieves Consistent, Spec-Compliant Lithium Carbonate Production from Automated Refining Unit in the Texas Permian Basin. Author: Joe Gantos, Senior Analyst Date: February 01, 2026 Recommendation: STRONG BUY Target Price (12-18 mo): C$3.00 – C$5.00 Current Price: C$1.39 Market […]
January 23rd Biotech Update
The sector continues to plod along. I think there is some interesting news with the oral GLP launch and while it certainly has import for the companies involved, I think the sector does best when there is a big launch that creates buzz outside the sector. It is the generalists that really push bull markets […]
January 20th Biotech Update
Heading into JPM, the sector was navigating a transition from volatility toward selective strength. After a challenging 2025 for venture funding and IPO activity, investors showed cautious optimism driven by increased M&A and improved clinical pipelines. Large pharmas continued to balance patent cliffs with new launches, while emerging biotech companies emphasized differentiated platforms in oncology, […]
January 9th Biotech Update- Pre-JPM
Biotech enters the JPM with constructive but selective risk appetite: public equity windows are open intermittently, valuation dispersion remains wide, and financing is available for differentiated clinical assets while earlier or “me-too” stories still struggle to clear diligence and pricing. The macro backdrop is supportive relative to the prior two years, where markets are rewarding […]
December 8th Biotech Update
Over the past two weeks, the biotech market has been shaped by a mix of both supportive macro forces and pockets of volatility tied to shifting risk sentiment. Cooling inflation data and growing expectations for rate cuts have provided a constructive backdrop, improving access to capital and lifting appetite for higher-beta sectors such as biotech. […]
LibertyStream – Makes History: First Field-Scale Lithium Production from U.S. Oilfield Brine
Chimera Research Group Critical Minerals Equity Note LibertyStream Infrastructure Partners Inc. (TSXV: LIB | OTCQB: VLTLF) Company Update: De-Risking Event – From Lab to First Commercial Lithium Carbonate Production in The Field. Author: Joe Gantos, Senior Analyst Date: December 2nd, 2025 Recommendation: STRONG BUY Target Price (12-18 mo): C$3.00 – C$5.00 Current Price: C$0.85 Market […]
November 4th Biotech Update
The sector remains volatile even as it seems to have emerged from the recent depression in the sector. There will be periods of increase volatility and pullbacks but I still think we have emerged from the doldrums and the general movement going forward will be higher even if we do have some periods of negative […]
October 27th Biotech Update
Some fireworks to start the week, although the news came out yesterday about the large deal. The more we see deals with continued lower movement of rates and the more we get some regulatory consistency, the better for the sector. Ideally we would like to see the government re-open to get the FDA working again […]
LibertyStream Infrastructure Partners – The Permian Brine Disruptor Poised for Commercial Liftoff
Chimera Research Group Critical Minerals Equity Note LibertyStream Infrastructure Partners Inc. (TSXV: LIB | OTCQB: VLTLF) Company Update: 14-Month De-Risking Sprint – From Lab to Commercial Scale in Record Time Author: Joe Gantos, Senior Analyst Date: October 27ᵗʰ, 2025 Recommendation: STRONG BUY Target Price (12-18 mo): C$3.00 – C$5.00 Current Price: C$.48 Market Cap: ~C$84 […]
Cardiol Therapeutics Unlocking Potential in Heart-Failure Therapy Through Significant LV Mass Reduction – A Comprehensive Report
Cardiol Therapeutics Inc. (NASDAQ/TSX: CRDL), a clinical-stage biopharmaceutical company specializing in anti-inflammatory and anti-fibrotic therapies for heart disease, has demonstrated promising proof-of-concept data from its Phase II ARCHER trial of CardiolRx™ in acute myocarditis. The trial's topline results, announced on August 6, 2025, highlight a “significant reduction in left ventricular (LV) mass”, a critical biomarker […]
October 16th Biotech Update
News continues to be generally positive for the sector and there is no reason to suspect that the broader trend for the sector will be higher. Obviously, there will be retrenchments and pullbacks but those will be opportunities to add to positions just as the rallies in the bear market were opportunities to trim positions. […]
October 14th Biotech Update
Over the past few days, biotech and pharmaceutical stocks have seen mixed but generally positive moves sparked by deal news and strong individual performers. This environment reinforces the more positive sentiment around the sector but with a preference now being placed on pipelines with strong differentiation, regulatory path clarity, or acquisition potential. It seems the […]
October 10th Biotech Update
There is a lot still to summarize and talk about and I will be slowly chipping away at what I see are key developments for the broader market as well as those companies I have followed in the past. This has a little bit of both to end the week. BTIG hosted a webcast with […]
October 8th Biotech Update
Biotech sentiment is cautiously constructive: the XBI is up about 15% year-to-date which is outpacing the broader health sector. While we have seen deals, the next stage would be the IPO window creaking open again—2025 has logged ~165 U.S. IPOs across sectors and fresh biopharma filings like BillionToOne point to improving risk appetite, even if […]
October 6th Biotech Update
It has been a little while but my job has been quite busy but I am going to get back into a rhythm of putting out notes. To be fair, the market has done better without me and it finally seems like sentiment has turned. Deals, data, rates, and reduced uncertainty have all either moved […]
Eupraxia’s EP-104GI Demonstrates Unprecedented Durability in EoE at One-Year Follow-Up
Eupraxia Pharmaceuticals Inc. (EPRX) – Investment Snapshot Date: September 02, 2025 Stock Price: US$5.48 | Market Cap: US$198M (as of 09/02/2025) Recommendation: Buy | Target Price: US$12.00 On September 2, 2025, Eupraxia Pharmaceuticals ($EPRX) released one-year results from Cohort 5 (48 mg dose, 12 injections of 4 mg each) of the Phase 1b/2a RESOLVE trial, […]
Advancing EoE Treatment Amid Biologic Setbacks: CLDX Failure Reinforces EPRX’s Edge
Eupraxia Pharmaceuticals Inc. (EPRX) – Investment Snapshot Date: August 20, 2025 Stock Price: US$5.39 | Market Cap: US$193M (as of 8/19/2025 close) Recommendation: Buy | Target Price: $12.00 On August 19, 2025, Celldex Therapeutics (CLDX) announced results from its Phase 2 trial of barzolvolimab in EoE. The monoclonal antibody (mAb) targeting KIT met its primary […]
Eupraxia Phase 2b RESOLVE Trial Update: A Promising Step Forward for EoE Treatment
Eupraxia Pharmaceuticals Inc. (EPRX) – Investment Snapshot Stock Price: US$5.40 | Market Cap: ~US$194M Recommendation: Buy | Target Price: US$12.00 On July 8, 2025, Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, TSX: EPRX) announced a significant milestone in its clinical development program, dosing the first patient in the placebo-controlled Phase 2b portion of the RESOLVE trial for […]
